REHOVOT, Israel and JERSEY CITY, New Jersey, April 11 Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader inthe development of microRNA-based diagnostics and therapeutics, announcedtoday it will present multiple posters at the upcoming annual AACR conferencein San Diego. The posters will include data on Rosetta Genomics' uniquemicroRNA-based technologies and how they may be applied to develop objectiveand standardized diagnostic tests and therapeutics for cancer. The event willtake place on April 12-16 at the San Diego Convention Center, California.
1. "A microRNA-based diagnostic assay for non-small cell lung cancer";Sunday April 13, exhibit hall B-F, poster section 7, poster board 6, abstract#946.
Rosetta Genomics has shown that a single microRNA can differentiatesquamous from non squamous NSCLC with high sensitivity and specificity. Theability of physicians to accurately differentiate squamous from non-squamousnon-small cell lung cancer (NSCLC) is an important treatment guide.Bevacizumab(1), an angiogenesis inhibitor and an important new modality oftherapy for non-squamous NSCLC, includes a black-box warning aboutsubstantially higher rates of severe or fatal hemorrhage among patients withsquamous NSCLC histology compared with non-squamous NSCLC.
2. "Identification of tumor origin using microRNA signature"; WednesdayApril 16, exhibit hall B-F, poster section 2, poster board 1, abstract #5039.Each year approximately 70,000 patients in the United States are diagnosedwith cancer of unknown primary (CUP). Accurately identifying the origin of ametastasis can be critical in guiding treatment decisions. Rosetta Genomicsscientists have designed a classifier which assigns a primary site to acancer sample based on the microRNA expression in the sample. The overallsensitivity of this classifier is approximately 85%, with two-thirds of thesamples being classified with high-confidence, reaching accuracy exceeding90% and specificity of 99%.
3. "Antisense oligonucleotides against microRNA as a novel therapy forhepatocellular carcinoma"; Sunday April 13, exhibit hall B-F, poster section32, poster board 12, abstract # 1505.
MicroRNAs' regulatory role makes them attractive potential targets fortherapeutics, through either their activation or suppression. RosettaGenomics Scientists, in collaboration with scientists from IsisPharmaceuticals, Inc., aim to identify microRNAs that are deregulated inhepatocellular carcinoma (HCC) and inhibit their activity through the use ofantisense oligos (ASO). ASOs that target microRNAs which prove to be involvedin the carcinogenic process can be used as potential novel therapeutic agentsfor the treatment of HCC.
4. "MicroRNA profiles in body fluids as a novel class of biomarkers",Wednesday April 16, exhibit hall B-F, poster section 3, poster board 22,abstract #5167.
Rosetta Genomics has developed an integrative robust platform forextracting and profiling of microRNAs from body fluids including from thecell-free fraction of these fluids. The protocol was successfully applied toall body fluids and cell-free fluids examined, including serum, urine,saliva, amniotic fluid and pleural fluid.
MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG